摘要
目的观察瑞舒伐他汀对2型糖尿病伴混合性高脂血症患者颈总动脉血管弹性功能的改善作用。方法本院内分泌科2010年1月~2011年1月就诊的67例2型糖尿病伴混合性高脂血症患者在饮食指导控制血糖血脂的基础上随机分为对照组和治疗组。对照组患者服用阿卡波糖,治疗组在阿卡波糖组治疗基础上加服瑞舒伐他汀,疗程均为8周。测量治疗前后两组患者血糖、血脂、血管弹性参数如血管的压力应变弹性系数(Ep)、硬化参数(β)、顺应性(AC)、管径增大指数(AI)和脉搏波传导速度(PWV)。结果对照组治疗前后血脂无显著变化,治疗组治疗后总胆固醇(TC)、低密度脂蛋白(LDL)和甘油三酯(TG)水平显著降低(P<0.01);对照组治疗前后血管弹性参数差异均无显著性,治疗组经治疗后Ep、β、AC、AI和PWV均显著改变(P<0.05),与对照组比较差异具有显著性(P<0.05),此外,与对照组比较,治疗组的Ep、β、AI和PWV变化值具有显著性(P<0.05);TC、LDL和TG变化值与β、AI、Ep和PWV变化值成正相关(P<0.05)。结论瑞舒伐他汀具有调节血脂紊乱及改善血管弹性的作用。
Aim To observe the effect of Rosuvastatin on vascular elasticity in type 2 diabetes complicated with hyperlipidemia. Methods 67 hyperlipidemia patients complicated with diabetes visiting endocrinology department of our hospital from January 2010 to January 2011 were randomly divided into control group and treatment group. The patients in control group received Acarbose, and those in treatment group received Acarbose plus Rosuvastatin. Duration of treatment was 8 weeks. Levels of blood glucose, blood lipid and the parameters of vascular elasticity such as EP, β,AC, AI and PWVI3, were measured in both groups before and after treatment. Results Blood lipid in control group didn' t significantly change after treatment (P 〉 0.05 ). Total cholesterol ( TC), low density lipoprotein (LDL) and triacylg- lycerol (TG) significantly decreased (P 〈 0.01 ) in treatment group. The parameters of vascular elasticity didn' t signifi- cantly change after treatment in control group, but Ep, 13, AC, AI and PWV significantly changed in treatment group (P 〈 0. 05 ) , and were significantly different from those in control group (P 〈 0.05 ). The changes of Ep, β, AI and PWV in treatment group were significantly different from those in control group ( P 〈 0. 05). The changes of TC, LDL and TG were positively related with Ep, β, AI and PWV (P 〈 0. 05). Conclusion Rosuvastatin may have a role in regulating blood lipid and protecting vascular elasticity.
出处
《中国动脉硬化杂志》
CAS
CSCD
北大核心
2011年第7期597-600,共4页
Chinese Journal of Arteriosclerosis
关键词
瑞舒伐他汀
高血脂
2型糖尿病
血管弹性
Rosuvastatin
Hyperlipidemia
Type 2 Diabetes
Vascular Elasticity